Balanced news tone
News Sentiment
ZVRA sentiment intelligence
Zevra Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
-4.3% over one week, -1.0% over four weeks, trend active, and materially above fair value.
Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 23 Jun 2026 11:30
- Source
- GlobeNewswire
Zevra Therapeutics (ZVRA) legal chief sells shares after RSU exercise
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 23 Jun 2026 07:00
- Source
- Stock Titan
Board member at Zevra (NASDAQ: ZVRA) receives 30,000-share option grant
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
Zevra Therapeutics (ZVRA) awards director 30,000 stock options
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- Stock Titan
ZVRA Stock Price and Chart — NASDAQ:ZVRA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 07:00
- Source
- TradingView
Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 12:30
- Source
- GlobeNewswire
Is Zevra Therapeutics (ZVRA) Using MIPLYFFA Patent Extensions To Deepen Its Rare-Disease Moat?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Market source
Zevra Therapeutics extends MIPLYFFA exclusivity to 2041
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 16:25
- Source
- Proactive
Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 11:30
- Source
- GlobeNewswire
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 May 2026 20:30
- Source
- GlobeNewswire
ZVRA - Zevra Therapeutics Inc Stock Price and Quote
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 13:23
- Source
- Finviz
There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 15 May 2026 07:00
- Source
- simplywall.st
Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 May 2026 07:00
- Source
- Market source
Zevra Therapeutics' (NASDAQ:ZVRA) Earnings Aren't As Good As They Appear
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 May 2026 07:00
- Source
- Market source
Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- simplywall.st
Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 11 May 2026 07:00
- Source
- Market source
Zevra Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 09 May 2026 07:00
- Source
- Market source
Is It Too Late To Consider Zevra Therapeutics (ZVRA) After The Recent Share Price Surge?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 May 2026 07:00
- Source
- Market source
FMR LLC reports 3.21M-share stake in Zevra Therapeutics (NASDAQ: ZVRA)
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 06 May 2026 07:00
- Source
- Stock Titan
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 May 2026 07:00
- Source
- Market source
Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Apr 2026 07:00
- Source
- Market source
Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
Is Zevra Therapeutics (ZVRA) Pricing Reflecting Its Strong Multi‑Year Share Price Performance
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Mar 2026 07:00
- Source
- Market source
Zevra Therapeutics Stock Pre-Market (+17%): Reports Massive Q4 EPS Beat
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 10 Mar 2026 07:00
- Source
- Trefis
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model (NASDAQ:ZVRA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Mar 2026 07:00
- Source
- Seeking Alpha
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jan 2026 08:00
- Source
- Seeking Alpha
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Nov 2025 08:00
- Source
- simplywall.st
Zevra Therapeutics (NASDAQ:ZVRA) Is Using Debt Safely
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 03 Nov 2025 08:00
- Source
- simplywall.st
What You Can Learn From Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) P/S After Its 26% Share Price Crash
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Sep 2025 07:00
- Source
- simplywall.st